alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>


<ARTICLE> 5

<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM AVITAR'S 
REPORT FOR THE SIX MONTHS ENDED MARCH 31, 1998 AND IS QUALIFIED IN ITS ENTIRETY
BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<MULTIPLIER>1000

       
<S>                                                          <C>
<PERIOD-TYPE>                                                 6-MOS    
<FISCAL-YEAR-END>                                             SEP-30-1998
<PERIOD-START>                                                OCT-01-1997
<PERIOD-END>                                                  MAR-31-1998
<CASH>                                                             52,716
<SECURITIES>                                                            0
<RECEIVABLES>                                                     332,686
<ALLOWANCES>                                                        3,200
<INVENTORY>                                                       138,245
<CURRENT-ASSETS>                                                  739,021
<PP&E>                                                            927,881
<DEPRECIATION>                                                    714,234
<TOTAL-ASSETS>                                                    967,387
<CURRENT-LIABILITIES>                                           1,638,221
<BONDS>                                                                 0
<PREFERRED-MANDATORY>                                                   0
<PREFERRED>                                                         6,572
<COMMON>                                                          173,698
<OTHER-SE>                                                      (929,256)
<TOTAL-LIABILITY-AND-EQUITY>                                      967,387
<SALES>                                                           939,794
<TOTAL-REVENUES>                                                  939,794
<CGS>                                                             894,454
<TOTAL-COSTS>                                                   1,911,149
<OTHER-EXPENSES>                                                        0
<LOSS-PROVISION>                                                        0
<INTEREST-EXPENSE>                                                 61,559
<INCOME-PRETAX>                                                   152,062
<INCOME-TAX>                                                            0
<INCOME-CONTINUING>                                           (1,021,108)
<DISCONTINUED>                                                  1,136,170
<EXTRAORDINARY>                                                         0
<CHANGES>                                                               0
<NET-INCOME>                                                      115,062
<EPS-PRIMARY>                                                         .01
<EPS-DILUTED>                                                         .01
        


</TABLE>
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsOn the Use of Optimization Techniques for Turbulence Model CalibrationThis article discusses the use of numerical optimization procedures to aid in the calibration of turbulence model coefficients. Such methods would increase the rigor and repeatability of the calibration procedure by requiring clearly defined and objective optimization metrics, and could be used to identify unique combinations of coefficient values for specific flow problems. The approach is applied to the re-calibration of an explicit algebraic Reynolds stress model for the incompressible planar mixing layer using the Nelder-Mead simplex algorithm and a micro-genetic algorithm with minimally imposed constraints. Three composite fitness functions, each based upon the error in the mixing layer growth rate and the normal and shear components of the Reynolds stresses, are investigated. The results demonstrate a significant improvement in the target objectives through the adjustment of three pressure-strain coefficients. Adjustments of additional coefficients provide little further benefit. Issues regarding the effectiveness of the fitness functions and the efficiency of the optimization algorithms are also discussed.Document ID20190025296Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsYoder, Dennis A.*(NASA Glenn Research Center Cleveland, OH, United States)*Orkwis, Paul D.*(Cincinnati Univ. OH, United States)*Date AcquiredMay 23, 2019Publication DateMay 1, 2019Subject CategoryFluid Mechanics And ThermodynamicsReport/Patent NumberGRC-E-DAA-TN65018E-19680NASA/TM-2019-220163Funding Number(s)WBS: 109492.02.03.01.05Distribution LimitsPublicCopyrightPublic Use Permitted.Technical ReviewSingle ExpertAvailable DownloadsNameType20190025296.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
<TABLE> <S> <C>

<PAGE>

<ARTICLE> 5
<MULTIPLIER> 1000

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          MAR-31-2000
<PERIOD-START>                             APR-01-1999
<PERIOD-END>                               OCT-03-1999
<CASH>                                          28,081
<SECURITIES>                                         0
<RECEIVABLES>                                  512,519
<ALLOWANCES>                                    56,842
<INVENTORY>                                    511,936
<CURRENT-ASSETS>                             1,026,487
<PP&E>                                         867,478
<DEPRECIATION>                                 350,476
<TOTAL-ASSETS>                               2,241,347
<CURRENT-LIABILITIES>                          584,429
<BONDS>                                      1,244,165
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           213
<OTHER-SE>                                     140,397
<TOTAL-LIABILITY-AND-EQUITY>                 2,241,347
<SALES>                                      1,075,149
<TOTAL-REVENUES>                             1,075,149
<CGS>                                          796,216
<TOTAL-COSTS>                                  796,216
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                 3,579
<INTEREST-EXPENSE>                              51,978
<INCOME-PRETAX>                                (3,932)
<INCOME-TAX>                                       543
<INCOME-CONTINUING>                            (5,076)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (5,076)
<EPS-BASIC>                                     (0.24)
<EPS-DILUTED>                                   (0.24)


</TABLE>
§ 333.310 Acne active ingredients. The active ingredient of the product consists of any of the following: ( a ) Benzoyl peroxide, 2.5 to 10 percent.
( b ) Resorcinol, 2 percent, when combined with sulfur in accordance with § 333.320(a).
( c ) Resorcinol monoacetate, 3 percent, when combined with sulfur in accordance with § 333.320(b).
( d ) Salicylic acid, 0.5 to 2 percent.
( e ) Sulfur, 3 to 10 percent.
( f ) Sulfur, 3 to 8 percent, when combined with resorcinol or resorcinol monoacetate in accordance with § 333.320.
[75 FR 9776, Mar. 4, 2010]
EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

      In connection  with the Quarterly  Report of Central  Wireless,  Inc. (the
"Company") on Form 10-QSB for the quarter ended March 31, 2003 as filed with the
Securities and Exchange  Commission on the date hereof (the  "Report"),  each of
the  undersigned,  in the capacities and on the dates  indicated  below,  hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to his knowledge:

          1. The Report fully complies with the requirements of Section 13(a) or
     15(d) of the Securities Exchange Act of 1934; and

          2. The  information  contained in the Report fairly  presents,  in all
     material respects,  the financial condition and results of operation of the
     Company.

Date: July 14, 2004                        By: /s/ Kenneth W. Brand
                                           -------------------------------------
                                           Name:  Kenneth W. Brand
                                           Title: Chief Executive Officer and
                                                  acting Principal Accounting
                                                  Officer

A signed  original of this written  statement  required by Section 906, or other
document  authentications,  acknowledging,  or otherwise  adopting the signature
that  appears  in typed  form  within the  electornic  version  of this  written
statement  required by Section 906, has been provided to Central Wireless,  Inc.
and will be retained by Central  Wireless,  Inc. and furnished to the Securities
and Exchange Commission or its staff upon request.
§ 529.443 Ciclesonide. ( a ) *Specifications.* A non-pressurized metered dose inhaler and drug cartridge combination containing a solution of 30 milligrams/milliliter of the prodrug ciclesonide. Each actuation releases 343 micrograms (mcg) of ciclesonide.
( b ) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Administer an initial dose of 8 actuations (2,744 mcg ciclesonide) twice daily for 5 days, followed by 12 actuations (4,116 mcg ciclesonide) once daily for 5 days.
( 2 ) *Indications for use.* For the management of clinical signs associated with severe equine asthma.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[86 FR 13188, Mar. 8, 2021]
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          FEB-28-1997
<PERIOD-END>                               NOV-30-1996
<CASH>                                           7,427
<SECURITIES>                                         0
<RECEIVABLES>                                      593
<ALLOWANCES>                                         0
<INVENTORY>                                    242,597
<CURRENT-ASSETS>                                     0
<PP&E>                                          10,217
<DEPRECIATION>                                   3,560
<TOTAL-ASSETS>                                 269,328
<CURRENT-LIABILITIES>                           22,023
<BONDS>                                        180,207
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,500
<OTHER-SE>                                      65,179
<TOTAL-LIABILITY-AND-EQUITY>                   269,328
<SALES>                                        158,423
<TOTAL-REVENUES>                               160,468
<CGS>                                          132,437
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                24,174
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                  3,857
<INCOME-TAX>                                       524
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     3,333
<EPS-PRIMARY>                                      .22
<EPS-DILUTED>                                        0
        

</TABLE>
#### § 573.900 Pyrophyllite.

Pyrophyllite (aluminum silicate monohydrate) may be safely used as the sole anticaking aid, blending agent, pelleting aid, or carrier in animal feed when incorporated therein in an amount not to exceed 2 percent in complete animal feed.
§ 207.21 When must initial registration information be provided? ( a ) Registrants must register each domestic establishment no later than 5 calendar days after beginning to manufacture, repack, relabel, or salvage a drug or an animal feed bearing or containing a new animal drug at such establishment.
( b ) Registrants must register each foreign establishment before a drug or an animal feed bearing or containing a new animal drug manufactured, repacked, relabeled, or salvaged at the establishment is imported or offered for import into the United States.
<PAGE> 1
Exhibit 3.01
                                                                124784
                                                              UTAH DIV OF
                                                            CORPORATIONS & UCC


                AMENDMENTS TO THE ARTICLES OF INCORPORATION
                                    OF
                         DRYDEN INDUSTRIES, INC.

Pursuant to the provisions of Section 16-10a-1001 et. seq. of the Utah Revised
Business Corporation Act, the undersigned corporation, hereinafter referred to
as the "Corporation," hereby adopts the following Amendments to the Articles
of Incorporation:

FIRST: The following Amendment to the Articles of Incorporation were duly
adopted by the board of directors and the shareholders of the corporation in
accordance with Section 16-10a-1003 of the Utah Revised Business Corporation
Act, at the Special Meeting of Shareholders held on January 27, 2000.


                                ARTICLE IV
                            AUTHORIZED SHARES

The Corporation is authorized to issue a total of 250,000,000 shares of common
stock having a par value $0.001 per share (hereinafter referred to as "Common
Stock").

The number of issued and outstanding shares entitled to vote on the Amendments
to the Articles of Incorporation was 124,000,000 of which number 70,000,000
shares voted in favor and none opposed.

IN WITNESS WHEREOF, the foregoing Amendment to the Articles of Incorporation
have been executed this 27th day of January, 2000.

                                       DRYDEN INDUSTRIES, INC.


                                       /S/Robert L. Matzig, President
# C_2014223EN.01000401.xml

| 14.7.2014 | EN | Official Journal of the European Union | C 223/4 |
| --- | --- | --- | --- |

14.7.2014

EN

Official Journal of the European Union

C 223/4

---

Action brought on 16 April 2014 — European Commission v Kingdom of Denmark

(Case C-190/14)

2014/C 223/05

Language of the case: Danish

Parties

Parties

Applicant: European Commission (represented by: E. Manhaeve, U. Nielsen, acting as Agents)

Applicant:

Defendant: Kingdom of Denmark

Defendant:

Form of order sought

Form of order sought

| — | Declare that, by failing to publish the final river basin management plans by 22 December 2009 and by failing to send a copy thereof to the Commission by 22 March 2010 and, in any event, by having failed to inform the Commission thereof, the Kingdom of Denmark has failed to fulfil its obligations under Directive 2000/60/EC of the European Parliament and of the Council of 23 October 2000 establishing a framework for Community action in the field of water policy; (1) |
| --- | --- |

—

Declare that, by failing to publish the final river basin management plans by 22 December 2009 and by failing to send a copy thereof to the Commission by 22 March 2010 and, in any event, by having failed to inform the Commission thereof, the Kingdom of Denmark has failed to fulfil its obligations under Directive 2000/60/EC of the European Parliament and of the Council of 23 October 2000 establishing a framework for Community action in the field of water policy; (1)

1

| — | order the Kingdom of Denmark to pay the costs. |
| --- | --- |

—

order the Kingdom of Denmark to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Denmark has repeatedly acknowledged — most recently by reply of 18 December 2013 to the Commission’s supplementary reasoned opinion — that none of Denmark’s four river basin districts are currently covered by a river basin management plan, and that a copy of the final river basin management plans for the six-year period ending 22 December 2015 has not been sent to the Commission.

The Commission finds that Denmark has still not complied with Article 13(1), (2) and (6) of the Directive. According to Denmark’s reply of 8 May 2013, the infringement of Article 13 of the Directive may be expected to continue until May 2014 (approximately 3,5 years after the prescribed time limit). Furthermore, it is the Commission’s view that Denmark has still not complied with the requirements of Article 15(1) of the Directive, under which the time limit for informing the Commission was set at 22 March 2010.

---

(1)  OJ 2000 L 327, p. 1.

1

---
§ 582.5930 Vitamin A. ( a ) *Product.* Vitamin A.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.
AFS-12-510-E 

October 12, 2012 

 Exemption No. 8840C 

 Regulatory Docket No. FAA-2006-26744 

Mr. David L. Jones 

Corporate Aviation Education Director 

Aviation Institute of Maintenance 

4455 South Boulevard 

Virginia Beach, VA 23452 

Dear Mr. Jones: 

This letter is to inform you that we have granted your petition to extend Exemption No. 8840, 

as amended. It explains the basis for our decision and describes its effect. 

The Basis for Our Decision 

By letter dated August 22, 2012, you petitioned the Federal Aviation Administration 

(FAA) on behalf of Technical Educational Services, Inc., d.b.a. Aviation Institute of 

Maintenance (Aviation Institute) (operating under Air Agency Certificate U5ET092K) for an 

extension of Exemption No. 8840, as amended. That exemption from § 65.75(a) of Title 14, 

Code of Federal Regulations allows Aviation Institute to administer the aviation mechanic 

general written test to students immediately following their successful completion of the 

general curriculum but before they meet the experience requirements of § 65.77. 

In your petition, you indicate that there has been no change in the conditions and reasons 

regarding public interest and safety that were the basis for granting the original exemption. 

The FAA has determined that good cause exists for not publishing a summary of the petition 

in the Federal Register. The requested extension of the exemption would not set a precedent, 

and any delay in acting on this petition would be detrimental to Aviation Institute. 
 2

Our Decision 

The FAA has determined that the justification for the issuance of Exemption No. 8840, as 

amended, remains valid with respect to this exemption and is in the public interest. 

Therefore, under the authority provided by 49 U.S.C. §§ 40113 and 44701, which the FAA 

Administrator has delegated to me, I grant your petition. 

The Effect of Our Decision 

Our decision extends the termination date of Exemption No. 8840, as amended, to 

February 28, 2015, unless sooner superseded or rescinded. 

All conditions and limitations of Exemption No. 8840 remain the same. This letter must be 

attached to, and is a part of, Exemption No. 8840. 

Sincerely, 

/s/ 

Raymond Towles 

Acting Director, Flight Standards 

 Service
EXHIBIT 32
----------




                         CERTIFICATIONS OF
        CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
                PURSUANT TO 18 U.S.C. SECTION 1350,
             AS ADOPTED PURSUANT TO SECTION 906 OF THE
                    SARBANES-OXLEY ACT OF 2002
        ---------------------------------------------------



     The following statement is provided by the undersigned to accompany
the Quarterly Report on Form 10-Q for the quarter ended March 31, 2009,
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be
deemed filed pursuant to any provision of the Securities Exchange Act of
1934 or any other securities law:

     Each of the undersigned certifies that the foregoing Report on
Form 10-Q fully complies with the requirements of Section 13(a) of the
Securities Exchange Act of 1934 (15 U.S.C. 78m) and that the information
contained in the Form 10-Q fairly presents, in all material respects, the
financial condition and results of operations of ALP Liquidating Trust.




                                     /s/   Gary Nickele
                                     ------------------------------
                                     Gary Nickele
                                     Chief Executive Officer




                                     /s/   Gailen J. Hull
                                     ------------------------------
                                     Gailen J. Hull
                                     Chief Financial Officer and
                                     Principal Accounting Officer
§ 524.575 Cyclosporine ophthalmic ointment. ( a ) *Specifications.* Each gram of ointment contains 2 milligrams of cyclosporine.
( b ) *Sponsor.* See No. 000061 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* Apply a 1 ⁄ 4-inch strip of ointment directly on the cornea or into the conjunctival sac of the affected eye(s) every 12 hours.
( 2 ) *Indications for use.* For management of chronic keratoconjunctivitis sicca (KCS) and chronic superficial keratitis (CSK) in dogs.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[60 FR 48651, Sept. 20, 1995, as amended at 62 FR 48940, Sept. 18, 1997; 79 FR 10967, Feb. 27, 2014]